Acute inflammation in the intestinal mucosa of the continent ileal reservoir (or pouch) in patients who have undergone ileostomy and restorative proctocolectomy (proctocolectomy, restorative).
Comprehensive, easy-to-understand information about this condition
How we create this content →The limited documentation surrounding pouchitis is primarily due to its rarity, affecting fewer than 5 in 10,000 individuals. This extreme rarity restricts the scope of systematic clinical studies and comprehensive characterizations of the condition. As a result, many clinical features and potential genetic factors remain undocumented, which can be frustrating for patients seeking information.
To navigate your care for pouchitis, consider consulting a gastroenterologist with specific expertise in inflammatory bowel diseases or pouch disorders. They can provide tailored management strategies. Additionally, you may explore clinical trials to access innovative treatments; check the active trials listed at ClinicalTrials.gov. While there are currently no patient organizations identified for pouchitis, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can offer valuable insights.
There are several orphan drugs designated for pouchitis, including (-)-Epigallocatechin 3-gallate, EXE-346, a Live Biotherapeutic Product containing eight strains of probiotic bacteria, metronidazole, recombinant human interleukin-10 fusion protein, Rifamycin, and vedolizumab. Additionally, there are currently 13 active clinical trials exploring various aspects of pouchitis. You can find more information about these trials at ClinicalTrials.gov by searching for pouchitis.
Actionable guidance for navigating care for pouchitis
To navigate your care for pouchitis, consider consulting a gastroenterologist with specific expertise in inflammatory bowel diseases or pouch disorders. They can provide tailored management strategies. Additionally, you may explore clinical trials to access innovative treatments; check the active trials listed at ClinicalTrials.gov. While there are currently no patient organizations identified for pouchitis, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can offer valuable insights.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding pouchitis is primarily due to its rarity, affecting fewer than 5 in 10,000 individuals. This extreme rarity restricts the scope of systematic clinical studies and comprehensive characterizations of the condition. As a result, many clinical features and potential genetic factors remain undocumented, which can be frustrating for patients seeking information.
To navigate your care for pouchitis, consider consulting a gastroenterologist with specific expertise in inflammatory bowel diseases or pouch disorders. They can provide tailored management strategies. Additionally, you may explore clinical trials to access innovative treatments; check the active trials listed at ClinicalTrials.gov. While there are currently no patient organizations identified for pouchitis, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can offer valuable insights.
There are several orphan drugs designated for pouchitis, including (-)-Epigallocatechin 3-gallate, EXE-346, a Live Biotherapeutic Product containing eight strains of probiotic bacteria, metronidazole, recombinant human interleukin-10 fusion protein, Rifamycin, and vedolizumab. Additionally, there are currently 13 active clinical trials exploring various aspects of pouchitis. You can find more information about these trials at ClinicalTrials.gov by searching for pouchitis.
Actionable guidance for navigating care for pouchitis
To navigate your care for pouchitis, consider consulting a gastroenterologist with specific expertise in inflammatory bowel diseases or pouch disorders. They can provide tailored management strategies. Additionally, you may explore clinical trials to access innovative treatments; check the active trials listed at ClinicalTrials.gov. While there are currently no patient organizations identified for pouchitis, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can offer valuable insights.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding pouchitis is primarily due to its rarity, affecting fewer than 5 in 10,000 individuals. This extreme rarity restricts the scope of systematic clinical studies and comprehensive characterizations of the condition. As a result, many clinical features and potential genetic factors remain undocumented, which can be frustrating for patients seeking information.
To navigate your care for pouchitis, consider consulting a gastroenterologist with specific expertise in inflammatory bowel diseases or pouch disorders. They can provide tailored management strategies. Additionally, you may explore clinical trials to access innovative treatments; check the active trials listed at ClinicalTrials.gov. While there are currently no patient organizations identified for pouchitis, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can offer valuable insights.
There are several orphan drugs designated for pouchitis, including (-)-Epigallocatechin 3-gallate, EXE-346, a Live Biotherapeutic Product containing eight strains of probiotic bacteria, metronidazole, recombinant human interleukin-10 fusion protein, Rifamycin, and vedolizumab. Additionally, there are currently 13 active clinical trials exploring various aspects of pouchitis. You can find more information about these trials at ClinicalTrials.gov by searching for pouchitis.
Actionable guidance for navigating care for pouchitis
To navigate your care for pouchitis, consider consulting a gastroenterologist with specific expertise in inflammatory bowel diseases or pouch disorders. They can provide tailored management strategies. Additionally, you may explore clinical trials to access innovative treatments; check the active trials listed at ClinicalTrials.gov. While there are currently no patient organizations identified for pouchitis, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can offer valuable insights.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
Organizations with orphan designations or approved therapies for this disease
Applied Molecular Transport, Inc.
Other
Avivia Project BV
Other
Bensen Therapeutics Limited
Other
Cosmo Technologies, Ltd.
Other
ExeGi Pharma, LLC.
Other
PharmassetX LLC
Other
S.L.A. Pharma Limited (UK)
Other
Takeda Development Center Americas, Inc.
Other